Humbert Michael, Rasmussen Robert A, Song Ruijiang, Ong Helena, Sharma Prachi, Chenine Agnès L, Kramer Victor G, Siddappa Nagadenahalli B, Xu Weidong, Else James G, Novembre Francis J, Strobert Elizabeth, O'Neil Shawn P, Ruprecht Ruth M
Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
Retrovirology. 2008 Oct 17;5:94. doi: 10.1186/1742-4690-5-94.
Infection of nonhuman primates with simian immunodeficiency virus (SIV) or chimeric simian-human immunodeficiency virus (SHIV) strains is widely used to study lentiviral pathogenesis, antiviral immunity and the efficacy of AIDS vaccine candidates. SHIV challenges allow assessment of anti-HIV-1 envelope responses in primates. As such, SHIVs should mimic natural HIV-1 infection in humans and, to address the pandemic, encode HIV-1 Env components representing major viral subtypes worldwide.
We have developed a panel of clade C R5-tropic SHIVs based upon env of a Zambian pediatric isolate of HIV-1 clade C, the world's most prevalent HIV-1 subtype. The parental infectious proviral clone, SHIV-1157i, was rapidly passaged through five rhesus monkeys. After AIDS developed in the first animal at week 123 post-inoculation, infected blood was infused into a sixth monkey. Virus reisolated at this late stage was still exclusively R5 tropic and mucosally transmissible. Here we describe the long-term follow-up of this initial cohort of six monkeys. Two have remained non-progressors, whereas the other four gradually progressed to AIDS within 123-270 weeks post-exposure. Two progressors succumbed to opportunistic infections, including a case of SV40 encephalitis.
These data document the disease progression induced by the first mucosally transmissible, pathogenic R5 non-clade B SHIV and suggest that SHIV-1157i-derived viruses, including the late-stage, highly replication-competent SHIV-1157ipd3N4 previously described (Song et al., 2006), display biological characteristics that mirror those of HIV-1 clade C and support their expanded use for AIDS vaccine studies in nonhuman primates.
用猿猴免疫缺陷病毒(SIV)或嵌合猿猴 - 人类免疫缺陷病毒(SHIV)毒株感染非人灵长类动物被广泛用于研究慢病毒发病机制、抗病毒免疫以及艾滋病候选疫苗的疗效。SHIV攻击可评估灵长类动物中抗HIV - 1包膜反应。因此,SHIV应模拟人类自然HIV - 1感染情况,并且为应对全球大流行,应编码代表全球主要病毒亚型的HIV - 1 Env组分。
我们基于世界上最流行的HIV - 1亚型——C亚型的赞比亚儿科分离株的env基因,开发了一组C亚型R5嗜性SHIV。亲代感染性前病毒克隆SHIV - 1157i在五只恒河猴中快速传代。在接种后第123周第一只动物出现艾滋病后,将感染的血液输注到第六只猴子体内。在这个晚期阶段重新分离出的病毒仍然完全是R5嗜性且可经黏膜传播。在此我们描述了这最初一组六只猴子的长期随访情况。两只猴子一直处于非进展期,而另外四只在暴露后123 - 270周内逐渐发展为艾滋病。两只进展期猴子死于机会性感染,包括一例SV40脑炎。
这些数据记录了首例经黏膜传播的致病性R5非B亚型SHIV诱导的疾病进展情况,并表明源自SHIV - 1157i的病毒,包括先前描述的晚期、具有高度复制能力的SHIV - 1157ipd3N4(Song等人,2006年),具有与HIV - 1 C亚型相似的生物学特性,支持它们在非人灵长类动物艾滋病疫苗研究中更广泛的应用。